Grüezi! Sie wurden auf, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
SMI 10'268 1.4%  SPI 13'166 1.5%  Dow 28'726 -1.7%  DAX 12'114 1.2%  Euro 0.9672 1.0%  EStoxx50 3'318 1.2%  Gold 1'661 0.0%  Bitcoin 19'151 0.5%  Dollar 0.9876 1.2%  Öl 87.9 -1.1% 
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
13.08.2022 00:59:00

Why Mind Medicine Stock Crushed the Market on Friday

A unique stock even among the many distinctive titles that make up the biotech sector, Mind Medicine (NASDAQ: MNMD) reported its second-quarter results after market hours on Thursday. This followed the publication earlier that day of a "value enhancement plan" from a onetime top official at the company. Combined, these two events pushed the specialty clinical-stage company's share price nearly 12% higher on Friday.For the quarter, Mind Medicine -- which is still in a pre-revenue stage -- managed to trim its expenses considerably, which certainly helped with investor sentiment on the stock. It booked just shy of $17 million in operating expenses. Thanks to a nearly $30 million decline in general and administrative costs, these expenses were well down from the Q2 2021 level of over $45 million. The company's net loss for both periods was roughly around those amounts.In per-share terms, Mind Medicine's bottom-line shortfall was $0.04, slightly better than the average $0.05 deficit estimated by the few analysts tracking the stock.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"


Viele Anleger setzen deshalb auf den Aktiv verwalteten Global Inflation Protection Basket. Informieren Sie sich über die breit gestreute Auswahl an robusten Aktien & ETFs.